Cocoa, blood pressure, and vascular function by Ludovici, Valeria et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Cocoa, blood pressure, and vascular function
Ludovici, Valeria; Barthelmes, Jens; Nägele, Matthias P; Enseleit, Frank; Ferri, Claudio; Flammer,
Andreas J; Ruschitzka, Frank; Sudano, Isabella
Abstract: Cardiovascular disease (CVD) represents the most common cause of death worldwide. The
consumption of natural polyphenol-rich foods, and cocoa in particular, has been related to a reduced
risk of CVD, including coronary heart disease and stroke. Intervention studies strongly suggest that
cocoa exerts a beneficial impact on cardiovascular health, through the reduction of blood pressure (BP),
improvement of vascular function, modulation of lipid and glucose metabolism, and reduction of platelet
aggregation. These potentially beneficial effects have been shown in healthy subjects as well as in patients
with risk factors (arterial hypertension, diabetes, and smoking) or established CVD (coronary heart
disease or heart failure). Several potential mechanisms are supposed to be responsible for the positive
effect of cocoa; among them activation of nitric oxide (NO) synthase, increased bioavailability of NO
as well as antioxidant, and anti-inflammatory properties. It is the aim of this review to summarize the
findings of cocoa and chocolate on BP and vascular function.
DOI: https://doi.org/10.3389/fnut.2017.00036
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-149863
Published Version
 
 
Originally published at:
Ludovici, Valeria; Barthelmes, Jens; Nägele, Matthias P; Enseleit, Frank; Ferri, Claudio; Flammer,
Andreas J; Ruschitzka, Frank; Sudano, Isabella (2017). Cocoa, blood pressure, and vascular function.
Frontiers in Nutrition, 4:36.
DOI: https://doi.org/10.3389/fnut.2017.00036
August 2017 | Volume 4 | Article 361
Review
published: 02 August 2017
doi: 10.3389/fnut.2017.00036
Frontiers in Nutrition | www.frontiersin.org
Edited by: 
Emilio Jirillo, 
Università degli studi di 
Bari Aldo Moro, Italy
Reviewed by: 
Honglin Dong, 
Coventry University, 
United Kingdom  
Nicolò Merendino, 
Università degli Studi della 
Tuscia, Italy  
Siu-Lung Chan, 
University of Vermont, 
United States
*Correspondence:
Isabella Sudano  
isabella.sudano@usz.ch
Specialty section: 
This article was submitted to 
Nutritional Immunology, 
a section of the journal 
Frontiers in Nutrition
Received: 06 April 2017
Accepted: 10 July 2017
Published: 02 August 2017
Citation: 
Ludovici V, Barthelmes J, Nägele MP, 
Enseleit F, Ferri C, Flammer AJ, 
Ruschitzka F and Sudano I (2017) 
Cocoa, Blood Pressure, 
and Vascular Function. 
Front. Nutr. 4:36. 
doi: 10.3389/fnut.2017.00036
Cocoa, Blood Pressure, and  
vascular Function
Valeria Ludovici1,2, Jens Barthelmes1, Matthias P. Nägele1, Frank Enseleit1,  
Claudio Ferri2, Andreas J. Flammer1, Frank Ruschitzka1 and Isabella Sudano1*
1 Cardiology, University Heart Center, University Hospital and University of Zurich, Zurich, Switzerland,  
2 Department of Life, Health and Environmental Sciences, University of L’Aquila, L’Aquila, Italy
Cardiovascular disease (CVD) represents the most common cause of death worldwide. 
The consumption of natural polyphenol-rich foods, and cocoa in particular, has been 
related to a reduced risk of CVD, including coronary heart disease and stroke. Intervention 
studies strongly suggest that cocoa exerts a beneficial impact on cardiovascular health, 
through the reduction of blood pressure (BP), improvement of vascular function, mod-
ulation of lipid and glucose metabolism, and reduction of platelet aggregation. These 
potentially beneficial effects have been shown in healthy subjects as well as in patients 
with risk factors (arterial hypertension, diabetes, and smoking) or established CVD (cor-
onary heart disease or heart failure). Several potential mechanisms are supposed to be 
responsible for the positive effect of cocoa; among them activation of nitric oxide (NO) 
synthase, increased bioavailability of NO as well as antioxidant, and anti-inflammatory 
properties. It is the aim of this review to summarize the findings of cocoa and chocolate 
on BP and vascular function.
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iNTRODUCTiON
Cardiovascular disease (CVD) represents the most common cause of death in the Western world, 
with an estimated 17.5 million people dying from CHD (coronary heart disease or stroke) every 
year (1). A nutraceutical approach has been proposed to counteract the increasing burden of CVD. 
The consumption of polyphenol-rich foods has been related to a lower risk of cardiovascular events 
(cardiovascular mortality, myocardial infarction, and stroke) both in the general population and 
in patients with cardiovascular risk factors in several interventional and epidemiological trials 
(2–5). Polyphenols are believed to be largely responsible for this protective role. Characterized as 
compounds with phenolic structural features (6), they are a class of natural bioactive substances with 
numerous anti-atherogenic properties including anti-inflammatory, anti-aggregating, and vasodila-
tory effects, the ability to lower blood pressure (BP), to prevent oxidation of low-density lipoprotein 
(LDL), and to improve glucose and lipid profiles (7).
Fruits, vegetables, tea, chocolate, and wine contain a high amount of polyphenols. Among them, 
cocoa beans are one of the richest known sources of flavonoids (8), and their protective properties 
have been recognized and used by several cultures among centuries. The origins of chocolate are usu-
ally traced back to the pre-Columbian populations, which were probably the first to cultivate cocoa 
plants. The consumption of cocoa, appreciated for its invigorating and healthy effects, differed from 
today: they used to dissolve dried cocoa beans in water, adding cinnamon and pepper to enhance 
their strong and bitter taste. With its arrival in Europe in the sixteenth century, cocoa was processed in 
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a sweet soft beverage and rapidly became a luxury item. In the last 
century, the words cocoa and chocolate became intensely linked 
to hypertension, diabetes, overweight, and obesity (9). However, 
in the last two decades the salutary cardiovascular effects of this 
ancient medicinal food have begun to be reevaluated, and these 
properties have been related to cocoa’s high content of flavonoids, 
members of the broader polyphenol class. The main constituents 
are flavanols, present as monomeric (−)-epicatechin and (+)-cat-
echin, together with their dimers, oligomers, and polymers, the 
so-called proanthocyanidins, responsible for cocoa bitterness 
when complexing with salivary proteins (10). Although flavanols 
are likely to be responsible for cocoa’s beneficial effects, they are 
lost during the conventional chocolate manufacturing process, so 
that the total flavanol content of commercial chocolate varies by 
more than 10-folds (11). Upon harvest, cocoa beans are usually 
fermented by environmental microbiota. This process creates 
flavor precursors that further develop during the roasting step, 
generating the peculiar cocoa flavors that define its quality (12). 
Fermentation and roasting significantly decreases the polyphenol 
and flavanol content of cocoa due to high temperature conditions 
and oxidation (13). Furthermore, alkalinization, used to modify 
cocoa color and give it a milder taste, results in a 60% decrease of 
total flavanol content (14). In humans, flavanol serum concentra-
tion increases in a dose-dependent manner after ingestion, reach-
ing its peak usually 2–3 h after cocoa intake (15, 16). Flavanols 
are still detectable in plasma 8 h after consumption (17). Cocoa 
is also rich in theobromine, a 3,7-dimethylated xanthine alkaloid, 
and minerals such as potassium or magnesium (18).
Several epidemiological (19–21) and interventional studies 
strongly suggest that cocoa consumption, as well as vegetables 
and fruit intake, has numerous beneficial effects on cardiovas-
cular health, including lowering of BP (22), improving vascular 
function (23), reducing of platelet aggregation and adhesion (24), 
having anti-inflammatory properties (25), and improving glucose 
and lipid metabolism (26). These positive effects have been found 
in healthy subjects (27) as well as in patients with risk factors 
(arterial hypertension, diabetes, and smoking) (28) or established 
CVD (coronary heart disease or heart failure) (29). Various 
potential mechanisms, including the increased bioavailability 
of nitric oxide (NO) and the anti-inflammatory and antioxidant 
effect, are supposed to be responsible for the protective properties 
of cocoa (30).
This review aims to summarize the effects of cocoa and choco-
late on BP and vascular function.
ePiDeMiOLOGiCAL eviDeNCe
After observing the Kuna Indians from Central America, research-
ers discovered how cocoa might be able to lower BP and extend 
life expectancy (31). Indeed, this population surprisingly had a 
very low incidence of hypertension when aging, despite having 
a high salt diet compared to other normotensive communities 
(32). Interestingly, this was not related to genetic factors, since the 
same population, migrated from the San Blas islands to Panama 
City for economic reasons, showed to have BP levels similar to 
other urban dwelling people (31). In addition, when compared 
to other American citizens, a marked reduction in cardiovascular 
mortality was noticed (33). To explain this difference, many 
environmental factors were investigated, such as differences in 
lifestyle or tobacco use, but ruled out as contributories. Finally, 
it was found that Island-Kuna, but not Mainland-Kuna, used to 
drink five cups of cocoa per day, which, moreover, was deter-
mined to be flavonoid-rich (approximate intake 900 mg per day, 
i.e., the suggested highest intake worldwide) (34).
Since then, many epidemiological studies confirmed the 
assumption that cocoa could be responsible for these findings. 
Flavonoid-rich foods intake, and particularly chocolate consump-
tion, were associated with a lower risk of death due to CVD in the 
Iowa Women’s Health Study (19). Subsequently, in the Zutphen 
Elderly Study, a similar reduction in cardiovascular mortality 
after chocolate consumption was reported. Comparing the groups 
with higher and lower chocolate intake, a reduction of 3.7 mmHg 
in systolic BP (SBP; 95% CI, −7.1 to −0.3 mmHg; p = 0.03) and 
a reduction of 2.1 mmHg in diastolic BP (DBP; 95% CI, −4.0 to 
−0.2 mmHg; p = 0.03) were observed. Higher chocolate intake 
was associated to significant reduction in cardiovascular mortal-
ity (adjusted relative risk 0.50, 95% CI, 0.32–0.78; p = 0.004) and 
all-cause mortality (adjusted relative risk 0.53, 95% CI, 0.39–0.72; 
p < 0.001) (20). In the Stockholm Heart Epidemiology Program, 
chocolate intake related to a reduced cardiovascular mortality 
after acute myocardial infarction (21). Furthermore, this reduc-
tion appeared to be dose dependent. Compared with those never 
consuming chocolate, the subjects consuming chocolate less than 
once, up to once or up to twice per week showed progressively 
decreasing hazard ratios for cardiac mortality [0.73 (95% CI, 
0.41–1.31), 0.56 (0.32–0.99), and 0.34 (0.17–0.70), respectively]. 
However, chocolate consumption was weakly associated with a 
lower rate of total mortality and non-fatal outcomes (21). The 
same findings emerged in two cohort studies of middle-aged 
Swedish women and men, in which daily moderate chocolate 
intake had an inverse association with chronic heart failure 
hospitalization and death (35, 36). Furthermore, in the National 
Heart, Lung, and Blood Institute Family Heart Study, chocolate 
intake correlated inversely with prevalent coronary heart disease 
in a general United States population (37). The most recent 
epidemiological data coming from the analysis of the European 
Prospective Investigation into Cancer Norfolk cohort support 
the prior findings (38). When compared to those who consumed 
no chocolate, subjects in the highest quintile of chocolate intake 
(15.6–98.8 g per day) demonstrated a significantly reduced rate of 
stroke (HR 0.77, 95% CI, 0.62–0.96) and cardiovascular mortal-
ity (HR 0.75, 95% CI, 0.62–0.92). Similar results emerged from a 
meta-analysis of 9 separate studies involving 157,809 participants 
(38). However, it is important to underline that none of these 
epidemiological studies focused on the amount of cocoa intake. 
Thus, it is not possible to make efficient comparison between the 
abovementioned studies.
COCOA AND BP: iNTeRveNTiONAL 
STUDieS
Arterial hypertension is a major modifiable risk factor for car-
diovascular and cerebrovascular disease (39). Every 10  mmHg 
TABLe 1 | Studies investigating cocoa and blood pressure.
Reference Year Study design Population Duration 
(weeks)
intervention Reduction 
of SBP/
DBP active 
group 
(mmHg)
Reduction 
of SBP/DBP 
control 
group 
(mmHg)
Fraga et al. (41) 2005 Randomized crossover 28 normotensive 2 High-flavanol milk (168 mg)/white chocolate −6/−5 −2/−1
Grassi et al. (42) 2005 Randomized crossover 15 normotensive 1 Dark (500 mg flavanols)/white chocolate −7/−4.2 −0.5/−0.3
Crews et al. (43) 2008 Randomized double-blind 
parallel
101 normotensive 6 Dark chocolate (397 mg flavanol) and cocoa 
drink (357 mg flavanol)/low-flavanol chocolate 
and drink
−3.58/−0.5 −3.05/−0.57
Mastroiacovo 
et al. (44)
2015 Randomized double-blind 
parallel
90 normotensive 8 High (993 mg)/intermediate (520 mg)/low 
(48 mg) flavanol cocoa drink 
−7.83/−4.77 −1.60/−1.57
Sansone et al. (27) 2015 Randomized double-blind 
parallel
100 normotensive 4 High (450 mg)/low-flavanol cocoa drink −4.4/−3.9 −1/0
Grassi et al. (23) 2015 Randomized double-blind 
crossover
20 normotensive 1 High (800, 500, 200, 80 mg)/low (0 mg) 
flavanol cocoa
−4.8/−3.03 –/–
Murphy et al. (45) 2003 Randomized double-blind 
parallel
32 normotensive 4 High (234 mg flavanols and procyanidins)/low-
flavanol chocolate
+2/−1 +3/0
Engler et al. (46) 2004 Randomized double-blind 21 normotensive 2 High (213 mg procyanidins, 46 mg 
epicatechin)/low-flavanol chocolate
−1/+0.9 −2.8/−0.1
Shiina et al. (47) 2009 Randomized single-blind 39 normotensive 2 Dark (550 mg flavanols)/white chocolate +4.6/+6.6 +4/+5.2
Njike et al. (48) 2011 Randomized crossover 44 normotensive 
overweight
6 High/low-flavanol cocoa drink +2.2/−0.5 −0.1/+0.8
Taubert et al. (49) 2003 Randomized crossover 13 hypertensive 2 Dark (500 mg flavanols)/white chocolate −5.1/−1.8 +0.4/+0.3
Taubert et al. (50) 2007 Randomized single-blind 
parallel
44 pre-hypertensive/
hypertensive
18 Dark(30 mg flavanols)/white chocolate −2.9/−1.9 +0.1/0
Grassi et al. (51) 2005 Randomized crossover 20 hypertensive 2 Dark (500 mg flavanols)/white chocolate −11.9/−8.5 −0.7/−0.6
Muniyappa et al. 
(52)
2008 Randomized double-blind 
crossover
20 hypertensive 2 High (900 mg)/low-flavanol drink −2/−3 −1/−4
Davison et al. (53) 2010 Randomized double-blind 
crossover
52 hypertensive 6 High (1,052 mg)/low-flavanol cocoa drink −5.3/−3 −2.1/+0.1
Grassi et al. (54) 2008 Randomized crossover 19 hypertensive 
with IGT
2 Dark (1,008 mg polyphenols)/white chocolate −3.8/−3.9 −0.1/−0.2
Davison et al. (55) 2008 Randomized parallel 49 normotensive 
obese or overweight
12 High (902 mg)/low-flavanol cocoa −1.9/−1.8 +4.2/+2.8
Rostami et al. (28) 2015 Randomized double-blind 60 hypertensive 
diabetic
8 Dark/white chocolate −5.9/−6.4 −1.1/+0.2
Monagas et al. 
(56)
2009 Randomized crossover 47 diabetics or 
more than 3 CV risk 
factors
4 Cocoa powder (495 mg polyphenols) with 
milk/milk
0.0/−2 −3/−3
De Palma et al. 
(57)
2016 Randomized crossover 32 patients with 
stable HF
4 High (1,064 mg)/low-flavanol dark chocolate −1.8/−4.2 −0.9/+2.9
IGT, impaired glucose tolerance; HF, heart failure; CHD, coronary heart disease; CV, cardiovascular; SBP, systolic blood pressure; DBP, diastolic blood pressure.
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reduction in SBP significantly reduces the risk of major cardio-
vascular events, CHD, stroke, and heart failure, which leads to 
a significant 13% reduction in all-cause mortality (40). To date, 
several interventional studies have assessed the efficacy of cocoa 
in lowering BP both in healthy subjects and in patients with 
cardiovascular risk factors (Table 1).
Compared to cocoa butter chocolate, the regular consumption 
(14 days) of flavanol-rich milk chocolate (168 mg flavanols) was 
significantly linked with the reduction of SBP (−6 mmHg) and 
DBP (−5 mmHg), as well as with LDL cholesterol and oxidative 
stress markers in 28 healthy individuals (41). Similarly, short-
term administration (7  days) of flavanol-rich dark chocolate 
significantly reduced SBP (p  <  0.05) and insulin resistance 
(p <  0.001) in 20 healthy subjects (42). In 101 normotensive 
subjects, randomized to receive dark chocolate bars (397  mg 
flavanols), cocoa beverage (357  mg flavanols), or matching 
placebo for 6  weeks, the flavanol-rich chocolate consumption 
reduced SBP by 3.58 mmHg, with no significant effect on DBP 
(43). Furthermore, in 90 “healthy” elderly subjects, a statistically 
significant improvement in BP (p <  0.0001), insulin resistance 
(p < 0.0001), and lipid peroxidation (p = 0.001) were seen after 
8 weeks in the high flavanol (993 mg, SBP: −7.83 ± 0.56 mmHg, 
DBP: −4.77 ± 0.37 mmHg) and intermediate flavanol (520 mg, 
SBP: −6.8  ±  0.59  mmHg, DBP: −3.2  ±  0.36  mmHg) intake 
groups in comparison to the low-flavanol group (48  mg, SBP: 
−1.6  ±  1.06  mmHg, DBP: −1.57  ±  0.61  mmHg). Moreover, 
flavanol consumption demonstrated a positive effect on cogni-
tive performance (44). In the recently published Flaviola Health 
Study, 100 healthy subjects were enrolled and randomized 
to cocoa flavanol (CF) containing drink (450  mg) or CF-free 
drink for 1 month (27). CF intake decreased SBP and DBP by 
4.4  mmHg (95% CI, 7.9–0.9  mmHg) and 3.9  mmHg (95% CI, 
6.7–0.9  mmHg), improved endothelial function, and showed 
a positive effect on total and LDL cholesterol. By applying the 
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Framingham Risk Score, CF intake significantly lowered the 
10-year risk for CHD, CVD, and cardiovascular death in so-far 
healthy people (27). Moreover, Grassi and colleagues recently 
demonstrated that 1 week of supplementation with either 80 or 
200 mg total flavanols (17 or 42 mg epicatechin, respectively) sig-
nificantly decreased BP in healthy individuals (23). In particular, 
they documented a decrease in BP (SBP: −4.8 ±  1.03  mmHg, 
p <  0.0001; DBP: −3.03 ±  1.07  mmHg, p =  0.0011), and an 
improvement in endothelial function (23). However, in four 
different studies, flavanol-rich cocoa (234, 259, 550, 805 mg fla-
vanols per day, respectively) did not improve BP levels compared 
to placebo in normotensive subjects (45–48).
The effect of cocoa consumption on BP was also assessed 
in hypertensive patients. In a randomized crossover trial, 13 
hypertensive patients were randomized to dark polyphenol-rich 
chocolate (500 mg polyphenols) or white chocolate. After 14 days, 
only polyphenol-rich chocolate decreased SBP by 5.1  mmHg 
and DBP by 1.8 mmHg; after consumption discontinuation, BP 
levels returned to pre-intervention values within 2  days (49). 
Moreover, in 46 mildly hypertensive patients, low chronic cocoa 
intake (30 mg flavanols per day for 18 weeks) reduced SBP by 
−2.9 ± 1.6 mmHg (p < 0.001) and DBP by −1.9 ± 1.0 mmHg 
(p < 0.001) compared to placebo (50). In a crossover study, 20 sub-
jects with never treated essential hypertension were randomized 
to dark (500 mg flavanols) or white chocolate (flavanol free) for 
15  days. Dark chocolate decreased ambulatory BP (24-h SBP: 
−11.9 ± 7.7 mmHg, p < 0.0001; 24-h DBP: −8.5 ± 5.0 mmHg, 
p <  0.0001) (p <  0.0001), serum LDL cholesterol (p <  0.05), 
and improved vascular function (51). However, in a different 
crossover study enrolling 20 hypertensive subjects, flavanol-rich 
cocoa intake (900 mg per day) did not improve BP after 2 weeks, 
compared to placebo (52). A subsequent study evaluated the 
minimum dose required for BP lowering. A population of 52 
subjects with untreated mild arterial hypertension was rand-
omized to receive cocoa beverage containing different doses of 
flavanols (33, 372, 712, or 1,052 mg per day, respectively). After 
6 weeks, only the highest flavanol dose (1,052 mg per day) dem-
onstrated a significant reduction in 24-h SBP (5.3 ± 5.1 mmHg; 
p = 0.001), DBP (3 ± 3.2 mmHg; p = 0.002), and mean arterial 
BP (3.8 ± 3.2 mmHg; p = 0.0004) (53).
Flavanol intake also demonstrated a positive effect in hyper-
tensive patients with impaired glucose tolerance (IGT) and 
diabetes mellitus. In particular, 19 hypertensive patients with 
IGT were randomized to receive flavanol-rich dark chocolate 
or flavanol-free white chocolate for 15  days. Dark chocolate 
reduced both SBP and DBP (SBP: −3.82 ±  2.40  mmHg; 24-h 
SBP: −4.52 ± 3.94 mmHg; DBP: −3.92 ± 1.98 mmHg; 24-h DBP: 
−4.17 ±  3.29  mmHg), total and LDL cholesterol (p <  0.0001) 
as well as improved vascular function and insulin sensitivity 
(p  <  0.05) (54). High-flavanol cocoa (902  mg) reduced SBP 
and DBP (SBP: −1.9  mmHg, DBP: −1.8  mmHg, p  <  0.05) 
and improved vascular function among overweight and obese 
adults (55). A recent study conducted on 60 subjects affected by 
hypertension and type 2 diabetes, randomized to flavanol-rich 
dark chocolate or white chocolate for 8  weeks, confirmed that 
flavanol-rich chocolate is effective in decreasing BP, fasting blood 
sugar, and triglyceride levels in patients with cardiovascular risk 
factors (28). However, in a high-risk population (three or more 
cardiovascular risk factors), flavanol-rich cocoa intake did not 
reduce BP values after 4 weeks (56).
Furthermore, in 24 heart failure patients, a 4 weeks consump-
tion of high-flavanol dark chocolate (1,064 mg flavanols per day) 
significantly reduced DBP and NT-proBNP levels, compared to 
low-flavanol dark chocolate intake (57).
Several meta-analyses evaluated the available evidence on 
this topic. Ried and colleagues analyzed 13 studies, revealing a 
BP reduction after cocoa consumption (mean BP change ± SE: 
SBP: −3.2 ±  1.9  mmHg, p =  0.001; DBP: −2.0 ±  1.3  mmHg, 
p = 0.003). The effect maintained statistical significance only for 
the studies evaluating hypertensive and pre-hypertensive patients 
(SBP: −5.0 ± 3.0 mmHg; p = 0.0009; DBP: −2.7 ± 2.2 mmHg, 
p =  0.01) (58). Desch and coworkers also provided a meta-
analysis including 10 randomized controlled trials involving 
either healthy subjects or patients with prehypertension/stage 
1 hypertension (297 individuals). Cocoa consumption was 
associated with a 4.5 mmHg reduction (95% CI, −5.9 to −3.2, 
p < 0.001) for SBP and a 2.5 mmHg reduction (95% CI, −3.9 
to −1.2, p < 0.001) for DBP (59). In the same year, a Cochrane 
review showed that flavanol-rich chocolate and cocoa products 
may have a statistically significant effect in lowering BP by 
2–3  mmHg in the short term [SBP (95% CI): −2.77  mmHg 
(−4.72 to −0.82), p  =  0.005; DBP (95% CI): −2.20  mmHg 
(−3.46 to −0.93), p = 0.006] (22). A recent published Cochrane 
review confirmed these findings, observing a small (2 mmHg) 
decrease in BP in the short term, more pronounced in the pre-
hypertensive/hypertensive population (60).
COCOA AND vASCULAR FUNCTiON: 
iNTeRveNTiONAL STUDieS
Endothelium, the smooth, continuous inner lining of blood ves-
sels, exhibits not only a barrier function but also synthetizes and 
releases a variety of vasoactive substances. Thus, the imbalance 
between vasodilating and vasoconstricting mediators results in 
endothelial dysfunction (61). The impairment of endothelial 
function is an early event in the development of atherosclerosis 
and is associated with CVD (62). Endothelial dysfunction of the 
forearm, as assessed by the flow-mediated dilation of the brachial 
artery (FMD), is recognized to be a powerful surrogate marker 
for cardiovascular events and cardiovascular mortality, both in 
healthy subjects (63) and in patients with CV risk factors (64). 
Thus, FMD has been used to evaluate the effects of different inter-
ventions on endothelial function. To date, various studies have 
subsequently assessed the effects of cocoa on vascular function 
(Table 2).
In 15 healthy subjects, CFs intake (1.4–10.9  mg/kg body 
weight) acutely improved FMD at 1, 2, 3, and 4 h after consump-
tion. The improvement in vascular function was comparable to 
the one induced by nitrate intake (65). Flavanol-rich chocolate 
(213 mg procyanidins, 46 mg epicatechin) consumption signifi-
cantly improved FMD in 21 healthy subjects also over a 2-week 
period (p = 0.024). Moreover, plasma epicatechin concentrations 
markedly increased after 2 weeks in the active treatment group, 
TABLe 2 | Studies investigating cocoa and vascular function.
Reference Year Study design Population Duration intervention Outcome
Rodriguez-
Mateos et al. 
(65)
2015 Randomized double-
blind crossover
15 healthy 
subjects
1,2,3,4 h CF-rich drink (1.4–10.9 mg/kg body weight) 
vs. nitrate or nutrient-matched flavanol-free 
drink
Improvement in FMD after flavanol  
and nitrate intake
Engler et al. 
(46)
2004 Randomized 
double-blind 
placebo-controlled
21 heathy 
subjects
2 weeks High flavonoid chocolate (213 mg 
procyanidins, 46 mg epicatechin) vs. low-
flavonoid chocolate
Improvement in FMD, increased 
epicatechin concentrations
Sansone et al. 
(27)
2015 Randomized double-
blind controlled 
parallel
100 healthy 
subjects
30 days CF-containing drink (450 mg) or a nutrient-
matched flavanol-free control bi-daily
Improvement in FMD, decreased SBP  
and DBP, decreased PWV
Grassi et al. 
(23)
2015 Randomized double-
blind crossover 
controlled
20 healthy 
subjects
5 weeks Five treatments with daily intake of 10 g 
cocoa (0, 80, 200, 500, 800 mg flavonoids)
Dose-dependent improvement in FMD, 
decreased PWV, and BP
Schroeter 
et al. (66)
2006 Randomized 
crossover
16 healthy 
subjects, 
isolated rabbit 
rings
2 h Drink with high flavonoid content Improvement in FMD, paralleled the 
appearance of flavanols in plasma
Heiss et al. 
(67)
2015 Randomized double-
blind controlled 
parallel
42 healthy 
subjects
14 days CF-containing drink (450 mg bid) vs. CF-free 
drink
Improvement in FMD, decreased PWV,  
and in total peripheral resistances
Shiina et al. 
(47)
2009 Randomized 
single-blind
39 healthy 
subjects
2 weeks 45 g commercially available dark chocolate 
vs. white chocolate
Improvement in coronary circulation as 
measured by coronary velocity flow reserve
Grassi et al. 
(51)
2005 Randomized 
crossover 
placebo-controlled
20 untreated 
hypertensive 
patients
15 days 100 g dark chocolate (21.91 mg catechin, 
65,97 mg epicatechin) vs. flavanol-free white 
chocolate
Improvement in FMD, decreased BP and 
LDL cholesterol, increased insulin sensitivity
Grassi et al. 
(54)
2008 Randomized 
crossover 
placebo-controlled
19 
hypertensive 
with IGT
15 days 100 g dark chocolate (36 mg catechin, 
110 mg epicatechin) vs. flavanol-free white 
chocolate
Improvement in FMD, decreased SBP  
and DBP, decreased insulin resistance
Heiss et al. 
(69)
2005 Randomized double-
blind crossover
11 smokers 2 h 100 ml cocoa drink with high (176–185 mg) 
or low (<11 mg) flavanol content
Improvement in FMD and increased 
circulating NO pool. Increased flavanol 
metabolites
Hermann et al. 
(70)
2006 Randomized 
placebo-controlled
20 smokers 2 h 40 g commercially available dark chocolate 
vs. white chocolate
Improvement in FMD, antioxidant status, 
and platelet function
Davison et al. 
(55)
2008 Randomized double-
blind placebo-
controlled parallel
49 obese and 
overweight 
patients
12 weeks Dietary high (902 mg) vs. low (36 mg) 
flavanol intake
Improvement in FMD
Njike et al. (48) 2011 Randomized 
controlled crossover
44 overweight 
patients
6 weeks Sugar-free cocoa beverage or placebo, 
sugar-sweetened cocoa beverage or 
placebo
Improvement in FMD, no change  
in weight
West et al. 
(71)
2014 Randomized double-
blind crossover 
placebo-controlled
30 overweight 
patients
30 days 37 g dark chocolate plus sugar-free cocoa 
beverage (flavanols 814 mg) vs. low-flavanol 
chocolate bar and cocoa-free and sugar-
free beverage
Unchanged FMD, increased basal diameter 
and peak diameter of the brachial artery, 
increased basal blood flow, in women 
decreased augmentation index
Balzer et al. 
(72)
2008 Randomized 
double-blind
41 diabetic 
patients
30 days Flavanol-rich cocoa (321 mg flavanols × 3) 
or a nutrient-matched control (25 mg 
flavanols × 3)
Improvement in FMD
Mellor et al. 
(73)
2013 Randomized double-
blind crossover 
controlled
10 diabetic 
patients
2 h 13.5 g of high vs. low-flavanol chocolate; 
60 min later, a 75 g oral glucose load
Improved endothelial function assessed 
by reactive hyperemia peripheral artery 
tonometry
Heiss et al. 
(74)
2003 Randomized double-
blind crossover
20 patients 
with at least 1 
CV risk factor
2 h Flavanol-rich cocoa drink (100 ml) Improvement in FMD and increased levels 
of nitrosated and nitrosylated species
Heiss et al. 
(75)
2010 Randomized double-
blind crossover 
controlled
16 CHD 
patients
30 days Dietary high (375 mg bid) vs. low (9 mg bid) 
flavanol cocoa drink
Improvement in FMD and mobilization  
of endothelial progenitor cells
Flammer et al. 
(29)
2012 Randomized 
double-blind 
placebo-controlled
20 heart failure 
patients
2 h and 
30 days
40 g commercially available dark chocolate 
vs. flavonoid-free placebo chocolate
Improvement in FMD of platelet function
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(Continued )
Reference Year Study design Population Duration intervention Outcome
Flammer et al. 
(76)
2007 Randomized 
double-blind
22 heart 
transplant 
patients
2 h 40 g commercially available  
dark chocolate vs. flavonoid-free  
placebo chocolate
Inducing coronary vasodilation, 
improvement in coronary endothelial 
function, and improvement  
in platelet function
Rassaf et al. 
(77)
2016 Randomized 
double-blind 
placebo-controlled
57 
hemodialytic 
patients
30 days CF-rich beverages (900 mg per  
study day) vs. flavanol-free  
beverages
Improvement in FMD decreased DBP. 
Ingestion of flavanols during HD alleviated 
HD-induced vascular dysfunction
Sansone et al. 
(68)
2017 Randomized double-
blind crossover
47 healthy 
subjects
High (820 mg)/low-flavanol cocoa  
drink with high (220 mg)/low 
methylxanthines content
CFs with methylxanthines increased 
epicatechin serum concentration,  
increased FMD decreased PWV  
and DBP compared with flavanols alone
Modified from Ref. (116).
FMD, flow-mediated dilation; endoPAT, reactive hyperemia peripheral artery tonometry; PWV, pulse wave velocity; CV, cardiovascular; NO, nitric oxide; CHD, coronary heart disease; 
HD, hemodialysis; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; CF, cocoa flavanol; IGT, impaired glucose tolerance.
TABLe 2 | Continued
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suggesting that the effect on vascular function was flavanol-
mediated (46). In the Flaviola Health Study, a 1-month CF intake 
increased FMD over control by 1.2% (95% CI, 1.0–1.4) and 
decreased pulse wave velocity by 0.4 m/s (95% CI, 0.8–0.04 m/s) 
(27). Furthermore, 20 healthy subjects were randomized to 
receive 5 treatments with daily intake of 10 g cocoa (0, 80, 200, 
500, and 800 mg cocoa flavonoids per day) in5 periods lasting 
1 week. A dose-dependent increase in FMD (from 6.2% to 7.3, 
7.6, 8.1, 8.2% after the different flavonoid doses, respectively) was 
found (23). In healthy individuals, an improvement in vascular 
function after high-flavanol cocoa intake has been demonstrated 
in subsequent studies (66, 67). Flavanol-rich chocolate intake 
was also demonstrated to significantly improve coronary cir-
culation in healthy adults, as assessed by coronary flow velocity 
reserve measurement with non-invasive transthoracic Doppler 
echocardiography (47). Interestingly, in a recently published ran-
domized double-blind trial, an interaction between flavanols and 
methylxanthines, such as theobromine and caffeine contained in 
cocoa, has been identified. In particular, methylxanthines were 
demonstrated to increase epicatechin metabolites plasma levels, 
thus affecting flavanols absorption, and to enhance the positive 
vascular effect of flavanols (68).
Flavanol intake improved FMD in hypertensive patients with 
normal (51) as well as IGT (54). Flavanol-rich cocoa beverage also 
acutely improved endothelium-dependent vasodilation, platelet 
function, and circulating bioactive NO in smokers (69, 70). In 20 
male smokers, dark chocolate, but not white chocolate, improved 
FMD after 2 h (7.0 vs. 4.4%, p = 0.026), and the effect lasted about 
8  h after ingestion (70). Furthermore, a statistically significant 
reduction in DBP and mean BP, and a parallel improvement in 
FMD was shown after high-flavanol cocoa intake in obese and 
overweight subjects (55). Moreover, the positive effect of cocoa 
consumption on endothelial function was not associated with 
weight gain (48). Conversely, in a subsequent study, an increase 
in basal and peak brachial artery diameter, with no consequent 
change in FMD, was assessed in a group of 30 overweight patients 
after 30  days high-flavanol chocolate intake (71). In a diabetic 
population, high-flavanol cocoa consumption was associated 
with statistically significant improvement in vascular function 
both acutely (after 2 h) and chronically (30 days) in two different 
studies (72, 73). Flavanol-rich cocoa intake improved FMD 
(from 3.4 to 6.3%, p < 0.001) after 2 days in a population with 
at least one cardiovascular risk factor, including history of CHD, 
hypertension, hyperlipidemia, diabetes, or current tobacco use 
(74). Altogether, these studies highlight the ability of CFs in 
improving vascular function in patients with cardiovascular risk 
factors.
The efficacy of flavanol intake on vascular function has been 
assessed also in a population of 16 CHD patients, randomized 
to receive flavanol-rich or low-flavanol cocoa for 30  days. 
Results showed a significant improvement in endothelial func-
tion by 48%, a decrease in SBP (mean change in active group: 
−4.2 ± 2.7 mmHg), and increasing levels of circulating angiogenic 
cells in the active treatment group compared with controls (75).
In a study from our group, 20 chronic heart failure patients 
were randomized to receive commercially available flavanol-rich 
chocolate or control chocolate (29). Flavanol-rich chocolate sig-
nificantly improved FMD from baseline levels of 4.98 ± 1.95, to 
5.98 ± 2.32% (p = 0.045 and 0.02 for between-group changes) 2 h 
after intake, and to 6.86 ± 1.76% after 4 weeks of daily consump-
tion (p = 0.03 and 0.004 for between groups). After flavanol-rich 
chocolate intake, platelet adhesion significantly decreased in the 
short term, but the effect was not sustained after 4  weeks. BP 
values and heart rate did not change. We also assessed the effect 
of flavanol-rich dark chocolate compared with control chocolate 
on coronary vascular function in 22 heart transplant recipients, 
patients characterized by severely impaired vascular function 
(76). Two hours after ingestion, flavanol-rich dark chocolate but 
not control chocolate induced significant coronary vasodilation 
(p < 0.01), improved coronary vascular function (p = 0.01), and 
decreased platelet adhesion.
Cocoa flavanols demonstrated to have a protective role 
also among patients with end-stage renal disease (ESRD). A 
population of 57 ESRD patients was randomized to receive either 
flavanol-rich beverage (900 mg) or placebo. Flavanol-rich cocoa 
improved endothelial function by 53% (p <  0.001) and allevi-
ated hemodialysis induced endothelial dysfunction (p < 0.001) 
after acute ingestion, with no effect on BP and heart rate. After 
4 weeks of treatment, cocoa improved vascular function by 18% 
and decreased DBP (p = 0.03) (77).
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In a meta-analysis of 11 chronic and 11 acute studies, Hooper 
and colleagues found strong beneficial effects of cocoa on FMD, as 
well as reductions in DBP and mean arterial pressure. Chocolate 
or cocoa improved FMD regardless of the dose consumed (78).
Based on the epidemiological evidence and the results from 
interventional studies, the European Food Safety Authority (EFSA) 
published a health claim about the effect of polyphenols derived 
from cocoa on cardiovascular risk factors, assessing that CFs “help 
maintaining the elasticity of blood vessels, which contributes to 
normal blood flow.” In order to obtain the claimed effect, they sug-
gested “to consume 200 mg of cocoa flavanols per day, provided 
by 2.5 g of high-flavanol cocoa powder or 10 g of high-flavanol 
dark chocolate, in the context of a balanced diet” (79). Conversely, 
Vlachojannis and coworkers asserted that only cocoa products 
with 100 mg epicatechin or CF doses of around 900 mg were able 
to achieve positive effects on FMD and BP, questioning the 200 mg 
flavanols/46 mg epicatechin dose recommended by the EFSA (80).
Currently, the COcoa Supplement and Multivitamin 
Outcomes Study (COSMOS; NCT02422745) is ongoing to 
assess the capability of a cocoa extract supplement (600  mg 
per day flavanols/80  mg epicatechin) compared to a standard 
multivitamin supplement, to reduce the risk of CVD and cancer 
among men aged 60 years and older and women aged 65 years 
and older. Concomitantly, an ancillary study (COSMOS-Mind; 
NCT03035201) is being conducted to evaluate the effects of such 
supplements on cognitive function.
PUTATive MeCHANiSMS
The protective role of CFs intake on BP and endothelial func-
tion is likely to come from its vasodilatory effect; the underlying 
mechanisms are multiple and not fully understood (30).
In this context, the increased NO availability and the subse-
quent vasodilation may play a central role. In young spontane-
ously hypertensive rats, epicatechin delayed the occurrence of 
arterial hypertension and reduced locomotor hyperactivity; these 
results were both mediated by increased NO bioavailability and 
erythrocyte deformability (81). Taubert and colleagues (50) dem-
onstrated that prolonged intake of small amounts of dark choco-
late (6.3 g per day for 18 weeks) reduced BP and improved NO 
production in a population of 44 pre-hypertensive individuals. In 
particular, dark chocolate intake reduced mean SBP by 2.9 mmHg 
(p < 0.001) and DBP by 1.9 mmHg (p < 0.001); these results were 
accompanied by a sustained increase of S-nitrosoglutathione, 
a source of bioavailable NO, by 0.23  nmol/L (p <  0.001) (50). 
Flavanols, and particularly flavanol-rich cocoa, elevate NO bio-
availability by both stimulating the NO synthase (eNOS) activity 
(82, 83) and increasing the availability of l-arginine (via reduction 
of its degradation by arginase) (84). Furthermore, in a rat model, 
flavanols prevented the elevation of BP induced by l-nitroarginine 
methyl ester (l-NAME), a powerful inhibitor of NOS (83). In 
addition, cocoa showed a similar inhibitor effect on endothelin-1 
production, a powerful vasoconstrictor (85, 86). Flavanols proved 
capable to induce both NO-mediated and endothelium-derived 
hyperpolarizing factor-mediated relaxation in a large number of 
arteries including the coronary arteries (87). Since NO degrada-
tion is mediated by free radicals, the improvement in vascular 
function is also related to the anti-inflammatory and antioxidant 
properties of cocoa (88). In a systematic review of the literature 
on polyphenols and oxidative stress, four studies reported statisti-
cally significant improvements in markers of oxidative stress and 
inflammation after flavanol-rich cocoa intake (89). A significant 
reduction in oxidative stress occurred when dark chocolate was 
administered to smokers as opposed to milk chocolate (90). 
Furthermore, a high dose (472.5 mg) of flavonoids through cocoa 
powder led to reduction in all oxidative and inflammatory markers 
in type 2 diabetics, and to a parallel improvement in endothelial 
function (1.7 ± 0.1 vs. 2.3 ± 0.1%, p = 0.01) assessed by reactive 
hyperemia peripheral artery tonometry (EndoPAT-2000) (73). 
After consumption of cocoa products, a decrease in markers of 
peroxidation was also observed in healthy subjects, as well as in 
obese, dyslipidemic, pre-hypertensive, and hypertensive patients 
(25). CFs directly scavenge ROS and nitrogen species (91); 
moreover, they modulate crucial enzymes related to oxidative 
stress, such as catalase, superoxide dismutase, glutathione per-
oxidase, glutathione reductase, glutathione transferase, xanthine 
oxidase, and lipooxygenase (92, 93). In line with this, the exposure 
of human endothelial cells to epicatechin inhibited endothelial 
NADPH oxidase, reduced superoxide and peroxynitrite levels, 
and consequently induced an increase in NO and cyclic guano-
sine monophosphate cellular levels (94). Furthermore, cocoa 
powder and epicatechin demonstrated to significantly decrease 
aortic oxidative stress and circulating markers related to impaired 
coagulation (von Willebrand factor, factor VIII, and fibrinogen) 
and inflammation (tissue necrosis factor-α, interleukin-6, inter-
leukin-10, and C-reactive protein) (95). In vitro experiments show 
that CFs inhibit pro-inflammatory cytokines such as interleu-
kin-2, interleukin-1β, and tissue necrosis factor-α, and positively 
modulate the expression of anti-inflammatory cytokines, such as 
interleukin-4 and transforming growth factor-β (92, 96–98).
An inhibition of angiotensin-converting enzyme (ACE) 
by cocoa constituents has been postulated. In a rat model, 
flavanol-rich cocoa powder significantly reduced BP in spon-
taneously hypertensive rats but did not exert a similar effect 
in normotensive Wistar-Kyoto rats. Interestingly, the effect of 
flavanol-rich cocoa (300 mg/kg) clearly mimicked that caused 
by captopril (50 mg/kg) (99). In 2006, Actis-Goretta and col-
leagues documented an in  vitro interaction between cocoa 
flavonoids and ACE. They demonstrated that procyanidin-rich 
chocolate significantly inhibited purified ACE activity, whereas 
the inhibitory activity correlated with both the phenolic con-
tent (p <  0.003) and the flavanol content (p <  0.001). When 
incubated in membrane suspensions from rat kidney, choco-
late [634  µM (+)-catechin equivalents] high in procyanidin 
inhibited ACE activity by 70% and such low in procyanidin 
[314  µM (+)-catechin equivalents] only inhibited ACE by 
45% (p <  0.001). The inhibition of ACE in tissue membrane 
suspensions was also observed in rat testes and lungs (100). In 
a subsequent study, extract from powdered cocoa beans was 
demonstrated to dose-dependently inhibit in vitro ACE activ-
ity; it also showed a dose-dependent radicals scavenging ability 
(101). Persson and colleagues (102) demonstrated that the acute 
consumption of dark chocolate (75 g, 72% of cocoa) inhibited 
ACE activity in  vitro—after incubation in human endothelial 
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FiGURe 1 | Cocoa flavanols and endothelial function. ACE, angiotensin-converting enzyme; A I, angiotensin I; A II, angiotensin II; ECE, endothelin-converting 
enzyme; ET 1, endothelin-1; EDHF, endothelium-derived hyperpolarizing factor; eNOS, endothelial NO synthase; l-NAME, l-nitroarginine methyl ester; ROS, reactive 
oxygen species; NO, nitric oxide; cGMP, cyclic guanosine monophosphate; cAMP, cyclic adenosine monophosphate; COX, cyclooxygenase; PGI2, prostacyclin; 
TXA2, thromboxane A2; SOD, superoxide dismutase; CF, cocoa flavanol. CFs improve endothelial function via different pathways. They increase NO availability, 
stimulating eNOS function, preventing l-NAME-induced hypertension, and reducing ROS. They also stimulate EDHF-mediated relaxation, inhibit endothelin-1, and 
reduce ACE activity. Modified by Corti et al., Circulation 2009.
cells from umbilical veins (HUVEC) —and in vivo in 16 healthy 
volunteers. In HUVEC, a significant inhibition of ACE activ-
ity (p <  0.01) and an increase of NO levels (p <  0.001) were 
seen. In healthy subjects, dark chocolate significantly inhibited 
ACE activity (mean 18%) 3 h after oral intake, with no relevant 
changes in circulating NO levels. According to ACE genotype, 
significant inhibition of ACE activity emerged in individuals 
with genotype insertion/insertion and deletion/deletion (mean 
21 and 28%, respectively) (102).
Recently, studies have begun to pay attention to the role of cocoa 
on mitochondria in cardiovascular health, as impaired mitochon-
drial function represents an early sign of endothelial dysfunction 
(103). The stimulation of mitochondrial function and biogenesis 
could ameliorate bioenergetic and metabolic status of cells, thereby 
improving vascular function and reducing CVD. Animal studies 
demonstrated that CFs are able to decrease cardiac post-ischemic 
damage via prevention of the mitochondrial permeability transi-
tion pore opening, and reduction in superoxide production (104); 
flavanols might also affect mitochondrial structure and function via 
stimulation of mitochondrial biogenesis (105). Patients, randomized 
to receive dark chocolate, showed increased maximal oxygen uptake 
and maximum work achieved, as well as increases in mitochondrial 
activity and glutathione levels, when compared to placebo (106). 
NO is suspected to mediate the effects of cocoa on mitochondria. 
In support of this thesis, a recent study demonstrated, in vitro, that 
flavanols are capable to stimulate mitochondrial function and bio-
genesis; effects disappeared with the inhibition of eNOS (107, 108).
Cocoa flavanols are also able to inhibit platelet activation, 
adhesion, and aggregation, mechanisms that play a central role in 
the development of endothelial dysfunction and atherosclerosis 
(109). Indeed, activated platelets secrete a number of adhesion 
molecules, such as P-selectin and C40 ligand, release inflamma-
tory mediators into the local microenvironment (110), stimulate 
the chemotaxis of leukocytes to the site of inflammation (111), 
and generate ROS, reducing NO bioavailability and contributing 
to endothelial dysfunction and thrombosis (112).
Moreover, cocoa and its main flavanols may improve vascular 
function by regulating the glucose and lipid profile (113), crucial 
risk factors for vascular damage. There is evidence that CFs are 
able to modulate insulin secretion in β-pancreatic cells, target 
insulin-sensitive tissues, repress glucose production, enhance 
glucose uptake through the promotion of glucose transport, and 
improve lipid metabolism (114).
Altogether, these mechanisms might determine the antihyper-
tensive and cardiovascular protective effects of flavanols in vivo 
(Figure 1).
CONCLUSiON
Polyphenol-rich foods, such as fruit, vegetables, wine, olive oil, 
and cocoa, are able to reduce cardiovascular risk and prevent 
cardiovascular events and death (3–5, 115). Among them, cocoa 
beans have always been of particular interest, as they are one of 
the richest polyphenol sources. In this context, several epidemio-
logical studies suggest a strong correlation between daily cocoa 
intake and better cardiovascular outcome in different population 
settings (19–21). Clinical interventional studies demonstrated a 
positive effect of flavanol-rich cocoa or chocolate intake on BP 
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reduction and improvement in microvascular and macrovascular 
function (116, 117). In vitro and in vivo studies identified increased 
NO availability, increased NO synthase activity, and inhibition of 
ACE as putative mechanisms of this beneficial effect (118).
Cocoa consumption has been demonstrated to improve 
endothelial function and to lower BP in healthy subjects, in patients 
with risk factors and hypertension, and in patients with coronary 
heart disease and heart failure. Furthermore, a 3-mmHg reduction 
in SBP has been estimated to lower the relative risk of CHD by 5% 
and the risk of global mortality by 4% (119). Thus, the introduction 
of a moderate amount of flavanol-rich cocoa in the daily diet may 
be a promising strategy to improve cardiovascular outcomes.
However, commercial chocolate with its high sugar and 
fat content may be undesirable in a population with increased 
cardiovascular risk. Furthermore, during the cocoa beans manu-
facturing process, the total amount of flavanols can be reduced 
more than 10-fold by fermentation or roasting (18). This results 
in an unpredictable content of polyphenols in most commercially 
available products. Moreover, the optimal dose of daily flavanol 
intake is still unclear. The EFSA recommends consuming 200 mg 
of CFs per day, provided by 2.5 g of high-flavanol cocoa powder 
or 10 g of high-flavanol dark chocolate in the context of a bal-
anced diet, but this dose has recently been subject of discussion 
(80). Thus, a comparison among studies is difficult, because of the 
heterogeneity between trials, in terms of study population and 
design, flavanol doses in active and control groups, and study 
duration.
Further clinical studies are required in order to identify the 
correct dose and the right modality of manufacturing of flavanol-
rich cocoa to be able to benefit from daily consumption of this 
natural medicinal product in the field of CVD.
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